Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
Clinical trial NCT04380519 · COMPLETED
Trial details
- NCT number
- NCT04380519
- Sponsor
- R-Pharm International, LLC
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-23
- Primary completion
- 2020-07-10
- Enrollment
- 372
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.